Pediatric non-alcoholic fatty liver disease: Recent advances

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 4, 2014, Pages 419-422

  Della Corte, Claudia ^a   Vajro, Pietro ^b   Socha, Piotr ^c   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL PEPTIDASE IV; INCRETIN; INSULIN SENSITIZING AGENT; OMEGA 3 FATTY ACID; PROBIOTIC AGENT;

BONE PROSTHESIS; CHILDHOOD DISEASE; FATTY ACID OXIDATION; GOLD STANDARD; HEPATIC PROGENITOR CELL; HEREDITY; HISTOPATHOLOGY; HISTORY; HUMAN; INFLAMMATION; INTESTINE FLORA; LIPID STORAGE; LIVER BIOPSY; LIVER INJURY; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; SCORING SYSTEM; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; CHILD; NON-ALCOHOLIC FATTY LIVER DISEASE;

CHILD; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84912533444     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.02.008     Document Type: Short Survey

References (20)

1. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
2. Nobili V., Svegliati-Baroni G., Alisi A., Miele L., Valenti L., Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013, 58:1218-1229.
3. Dongiovanni P., Anstee Q.M., Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013, 19:5219-5238.
4. Nobili V., Donati B., Panera N., Vongsakulyanon A., Alisi A., Dallapiccola B., et al. A Four-Polymorphisms Risk Score predicts steatohepatitis in children with non-alcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2013, [Epub ahead of print].
5. Frasinariu O.E., Ceccarelli S., Alisi A., Moraru E., Nobili V. Gut-liver axis and fibrosis in non-alcoholic fatty liver disease: an input for novel therapies. Dig Liv Dis 2013, 45:543-551.
6. Vajro P., Paolella G., Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013, 56:461-468.
7. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
8. Nobili V., Carpino G., Alisi A., Franchitto A., Alpini G., De Vito R., et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012, 56:2142-2153.
9. Alkhouri N., De Vito R., Alisi A., Yerian L., Lopez R., Feldstein A.E., et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 2012, 57:1312-1318.
10. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
11. Vajro P., Lenta S., Socha P., Dhawan A., McKiernan P., Baumann U., et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012, 54:700-713.
12. Patton H.M., Sirlin C., Behling C., Middleton M., Schwimmer J.B., Lavine J.E. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006, 43:413-427.
13. Schwimmer J.B., Dunn W., Norman G.J., Pardee P.E., Middleton M.S., Kerkar N., et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010, 138:1357-1364.
14. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
15. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2011, 56:255-266.
16. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
17. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
18. Ma Y.Y., Li L., Yu C.H., Shen Z., Chen L.H., Li Y.M. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013, 19:6911-6918.
19. Vajro P., Mandato C., Licenziati M.R., Franzese A., Vitale D.F., Lenta S., et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011, 52:740-743.
20. Nobili V., Alisi A., Della Corte C., Risè P., Galli C., Agostoni C., et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013, 23:1066-1070.